TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19180516
Drug: Pamapimod 150
Normalized name: Pamapimod
DrugBank: Pamapimod (DB19169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamapimod 150 mg
Study: 19180516
Drug: Pamapimod 300
Normalized name: Pamapimod
DrugBank: Pamapimod (DB19169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamapimod 300 mg
Study: 19180516
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg/week with planned escalation to 20 mg/week
Study: 18156171
Drug: Bortezomib combined
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib combined with chemotherapeutic agents
Study: 1357864
Drug: Prednicarbate ointment
Normalized name: Prednicarbate Ointment
DrugBank: Prednicarbate (DB01130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednicarbate ointment
Study: 1357864
Drug: Betamethasone-17-valerate ointment
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone-17-valerate ointment
Study: 3860789
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel (4 mg)
Study: 3860789
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel (4 mg) in subsequent open study
Study: 29705218
Drug: BH4 (Kuvan;
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH4 (Kuvan; BioMarin Pharmaceutical Inc)
Study: 22492370
Drug: High-tomato-based diet
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-tomato-based diet (equivalent to 32-50 mg lycopene/d)
Study: 22492370
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet supplemented with lycopene capsules (10 mg/d)
Study: 12375212
Drug: New intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: New intervention in rehabilitation medicine
Study: 7762493
Drug: verapamil 180
Normalized name: verapamil 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 180 mg
Study: 7762493
Drug: verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 360 mg
Study: 7762493
Drug: verapamil 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 540 mg
Study: 31299617
Drug: Se-rich lentils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-rich lentils (55 μg Se/day)
Study: 31299617
Drug: Control lentils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control lentils (1.5 μg Se/day)
Study: 28467661
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of supplemental elemental calcium daily
Study: 28467661
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g of supplemental elemental calcium daily
Study: 15579516
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg (A300)
Study: 15579516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aliskiren 150 mg and Valsartan 80 mg (A150+V80)
Study: 2736402
Drug: Tyrosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (100 mg/kg)
Study: 30316955
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with prostatism under medication
Study: 31952657
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) chemotherapy
Study: 31952657
Drug: Dose-dense i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense i.v. paclitaxel and carboplatin
Study: 23879944
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg loading dose prior to PCI followed by 20 mg Tid after PCI)
Study: 21924015
Drug: Bifidobacteria (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacteria (one capsule per time, for 7 days)
Study: 19737963
Drug: Curcumin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (4 grams/day oral)
Study: 16718762
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of ranitidine
Study: 16718762
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of ranitidine
Study: 16718762
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of bismuth
Study: 16718762
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of bismuth
Study: 9215608
Drug: MPA oral
Normalized name: FYCOMPA Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA oral suspension at a daily dose of 1000 mg for 12 weeks
Study: 2940334
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin (HBIG) - 3 or 4 doses in different schedules
Study: 2940334
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months
Study: 2940334
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months + HBIG - 1 dose at birth
Study: 28095549
Drug: SSR (mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSR (mass market topical products)
Study: 23232292
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (group 2A)
Study: 23232292
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (group 2B)
Study: 23232292
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (group 3A)
Study: 23232292
Drug: No recanalization
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recanalization therapy (group 3B)
Study: 23232292
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (overall)
Study: 17904278
Drug: Topical prilocaine-lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prilocaine-lidocaine cream combined with periprostatic nerve block (PNB)
Study: 16925853
Drug: High-quercetin soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quercetin soup (69 mg total quercetin)
Study: 16925853
Drug: Low-quercetin soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-quercetin soup (5 mg total quercetin)
Study: 12955551
Drug: Riluzole 200
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 200 mg
Study: 8633830
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.03 mg/kg of body weight) given three times a week for 6 months
Study: 6396971
Drug: Polyvinylpyridine N-oxide
Normalized name: Pyridinethiol N-oxide
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvinylpyridine N-oxide (PVNO) infusion, 300-400 mg per kg bodyweight, administered in intervals of one to two years
Study: 29262859
Drug: Danshen extract
Normalized name: DANSHEN EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen extract (DanshenDuofensuanyan injection and Danshen drop spill)
Study: 25728021
Drug: IGIV-C treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C treatment
Study: 24002945
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression
Study: 11245451
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of beta-carotene per day
Study: 7761550
Drug: Pulse-loading group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-loading group received 150 and 200 mg of clomipramine (CMI) on 2 consecutive evenings followed by placebo for 8 days
Study: 7761550
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing group began at 50 mg of CMI with gradual increases every second day until 200 mg was reached
Study: 3073805
Drug: Standard theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard theophylline (300 mg twice daily)
Study: 3073805
Drug: Titrated theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated theophylline (doses ranged from 300 mg to 700 mg twice daily)
Study: 3073805
Drug: Titrated theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated theophylline (for subgroup with titrated dose greater than standard)
Study: 25887970
Drug: Intervention for
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention for improving medication adherence and asthma control
Study: 16549964
Drug: CART and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART and rofecoxib 25 mg bid
Study: 16549964
Drug: CART and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART and celecoxib 400 mg bid
Study: 9194110
Drug: COMVAX (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMVAX (7.5 micrograms of PRP/5 micrograms of HBsAg in 0.5 ml)
Study: 30712747
Drug: Gua Sha
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua Sha therapy (n=25)
Study: 24438512
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mesenchymal stem cells (MSC) delivered via intra-arterial injection
Study: 19448234
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% ropivacaine with 0.5 microg/mL sufentanil (Group 1)
Study: 19448234
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.2% ropivacaine with 0.5 microg/mL sufentanil (Group 2)
Study: 19448234
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL saline (Group 3)
Study: 14653084
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline (Group A)
Study: 14653084
Drug: esmolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 0.5 mg/kg (Group B)
Study: 14653084
Drug: esmolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1.0 mg/kg (Group C)
Study: 14653084
Drug: esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1.5 mg/kg (Group D)
Study: 14653084
Drug: esmolol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 2.0 mg/kg (Group E)
Study: 11045293
Drug: Vancomycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1000 mg i.v. 12 hours before procedure)
Study: 11045293
Drug: Cefazolin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1000 mg i.v. 3 hours before procedure)
Study: 11045293
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotics for at least one week before procedure)
Study: 9186325
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin (50 mg)
Study: 9186325
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin (80 mg)
Study: 9186325
Drug: Intravesical doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical doxorubicin (50 mg)
Study: 1607691
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (250 mg twice a day)
Study: 1607691
Drug: Vitamin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin (one tablet daily)
Study: 4029717
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 80 mg at 0900 and 40 mg at 1700
Study: 4029717
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 80 mg at 0900 and 80 mg at 1700
Study: 4029717
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 80 mg at 0900, 40 mg at 1700 and 40 mg at 0100
Study: 21970545
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg b.i.d. plus clomiphene citrate (CC) 100 mg on cycle days 3‐7
Study: 10338443
Drug: darifenacin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: darifenacin 5 mg t.d.s.
Study: 8758748
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments with anti-tuberculous drugs (Control)
Study: 1929764
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group treatment program
Study: 1929764
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with phenelzine sulfate
Study: 1929764
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with alprazolam
Study: 1929764
Drug: Pill-placebo plus
Normalized name: Interceptor Plus Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-placebo plus instructions for self-directed exposure to phobic stimuli
Study: 31030995
Drug: Iclaprim 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim 80 mg fixed dose
Study: 31030995
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg administered intravenously during 2 h every 12 h for 5–14 days
Study: 25612845
Drug: Fentalgon® (bilayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentalgon® (bilayer matrix type patch)
Study: 25612845
Drug: Durogesic SMAT
Normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Durogesic SMAT (monolayer matrix type patch)
Study: 24402597
Drug: Patch (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch (13 cycles)
Study: 24402597
Drug: Pill (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill (6 cycles) followed by Patch (7 cycles)
Study: 24402597
Drug: Pill
Normalized name: PILL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill
Study: 21536692
Drug: Escitalopram (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (up to 20 mg/day) plus placebo
Study: 21536692
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (up to 400 mg/day) plus escitalopram (up to 20 mg/day)
Study: 21536692
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine (up to 300 mg/day) plus mirtazapine (up to 45 mg/day)
Study: 17762959
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 mcg, titrated up to 50 mcg)
Study: 17762959
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg, titrated up to 5 mg)
Study: 1908864
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg q 6hr)
Study: 1908864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of indomethacin and misoprostol (200 mcg q 6hr)
Study: 1908864
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 mcg q 6hr)
Study: 6981965
Drug: Dulcolax (bisacodyl)
Normalized name: Dulcolax
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulcolax (bisacodyl) plus 2 L tapwater enema
Study: 6981965
Drug: Dulcolax or
Normalized name: Dulcolax Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulcolax or castor oil or X‐Prep, each with 2 L water enema
Study: 30037692
Drug: CAD-CAM systems
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD-CAM systems (group L, group iT, group C)
Study: 25924969
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus erlotinib (150 mg/day)
Study: 25924969
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus erlotinib (150 mg/day)
Study: 22031172
Drug: Anacetrapib co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib co-administered with digoxin
Study: 20380111
Drug: Intravenous pantoprasole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprasole (continuous regimen: 5 x 40 mg in continuous infusion of 8 mg/h for 72 h)
Study: 20380111
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (40 mg bolus of PPI twice daily for 3 days)
Study: 17130943
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg IV (Group 1, n=40)
Study: 17130943
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg IV (Group 2, n=40)
Study: 17130943
Drug: Ondansetron 2
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 2 mg IV (Group 3, n=40)
Study: 10613615
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral metoprolol tartrate twice daily for a total of nine doses
Study: 16112720
Drug: Methamphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (30 mg, IV)
Study: 12161475
Drug: T patch
Normalized name: Icy Hot Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: T patch alone (Testoderm TTS, 5 mg/d)
Study: 12161475
Drug: Norplant II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant II (Jadelle, 160 microg/d LNG) plus T patch
Study: 12161475
Drug: Oral LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LNG (125 microg/d) plus T patch
Study: 12161475
Drug: Norplant II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant II plus T enanthate (TE) injection (100 mg/wk i.m.)
Study: 7575695
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cM‐T412
Study: 7575695
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cM‐T412
Study: 7575695
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cM‐T412
Study: 24701774
Drug: Dynamic stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic stabilization system (ligamentoplasty) placed in the segment above (group L)
Study: 22090496
Drug: Voluntary action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary action preparation
Study: 17302061
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment beginning with Fei (SLE I formula in active stage or SLE II formula in silent period)
Study: 9782602
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (3 x 400 mg RRR‐alpha‐Tocopherolacetat/d)
Study: 26083656
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (325 mg three times daily for 8 weeks)
Study: 26083656
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg every 2 weeks, total 1 g)
Study: 23016924
Drug: ABT-288 single
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 single doses (0.1, 0.3, 1, 3, 10, 20, and 40 mg)
Study: 23016924
Drug: ABT-288 multiple
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 multiple doses (0.5, 1.5, 3, and 6 mg once-daily for 14 days in young adults)
Study: 23016924
Drug: ABT-288 multiple
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 multiple doses (0.5, 1.5, 3, and 5 mg once-daily for 12 days in elderly subjects)
Study: 23016924
Drug: ABT-288 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-288 (5 mg single dose) with food
Study: 21118746
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of oral risperidone 2 mg
Study: 21118746
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of oral risperidone 2 mg
Study: 18200463
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose diathermy technique
Study: 12811310
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 7 days
Study: 12811310
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily for 7 days
Study: 8923017
Drug: Various combinations
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combinations of vitamins and minerals at supranutritional doses
Study: 6391784
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg (for cisplatin >= 100 mg/sq m) or 1.25 mg (for subsequent doses < 100 mg/sq m)
Study: 6391784
Drug: Metoclopramide 2
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 2 mg/kg (for cisplatin >= 100 mg/sq m) or 1 mg/kg (for subsequent doses < 100 mg/sq m)
Study: 6391784
Drug: Prochlorperazine 5
Normalized name: prochlorperazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 5 mg (for both dosages of cisplatin)
Study: 27008285
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation therapy